下修肿瘤业务全年收入指引，和黄医药H股今日收跌近16%，美股盘前跌超5.5%

动脉网2025-08-08

和黄医药因下调肿瘤/免疫业务全年收入指引，导致H股今日收跌近16%，美股盘前跌超5.5%。公司上半年综合收入约2.8亿美元，同比跌9%；纯利逾4.5亿美元，同比增16.6倍。然而，肿瘤/免疫业务综合收入为1.4亿美元，同比跌15%。公司将全年收入指引从3.5亿-4.5亿美元下修至2.7亿-3.5亿美元，主要原因是合作伙伴的里程碑收入延后及索乐匹尼布在中国的新药上市申请审评推迟。瑞银研报指出，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557544747?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-08 16:43","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557544747","market":"hk","top_or_hot":-1,"title":"下修肿瘤业务全年收入指引，和黄医药H股今日收跌近16%，美股盘前跌超5.5%","media":"动脉网","content":"<div>\n<p>和黄医药因下调肿瘤/免疫业务全年收入指引，导致H股今日收跌近16%，美股盘前跌超5.5%。公司上半年综合收入约2.8亿美元，同比跌9%；纯利逾4.5亿美元，同比增16.6倍。然而，肿瘤/免疫业务综合收入为1.4亿美元，同比跌15%。公司将全年收入指引从3.5亿-4.5亿美元下修至2.7亿-3.5亿美元，主要原因是合作伙伴的里程碑收入延后及索乐匹尼布在中国的新药上市申请审评推迟。瑞银研报指出，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808171053973b7653&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>下修肿瘤业务全年收入指引，和黄医药H股今日收跌近16%，美股盘前跌超5.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n下修肿瘤业务全年收入指引，和黄医药H股今日收跌近16%，美股盘前跌超5.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-08 16:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808171053973b7653&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>和黄医药因下调肿瘤/免疫业务全年收入指引，导致H股今日收跌近16%，美股盘前跌超5.5%。公司上半年综合收入约2.8亿美元，同比跌9%；纯利逾4.5亿美元，同比增16.6倍。然而，肿瘤/免疫业务综合收入为1.4亿美元，同比跌15%。公司将全年收入指引从3.5亿-4.5亿美元下修至2.7亿-3.5亿美元，主要原因是合作伙伴的里程碑收入延后及索乐匹尼布在中国的新药上市申请审评推迟。瑞银研报指出，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808171053973b7653&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808171053973b7653&s=b","article_id":"2557544747","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808171053973b7653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557544747","pubTimestamp":1754642580,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"和黄医药因下调肿瘤/免疫业务全年收入指引，导致H股今日收跌近16%，美股盘前跌超5.5%。公司上半年综合收入约2.8亿美元，同比跌9%；纯利逾4.5亿美元，同比增16.6倍。然而，肿瘤/免疫业务综合收入为1.4亿美元，同比跌15%。公司将全年收入指引从3.5亿-4.5亿美元下修至2.7亿-3.5亿美元，主要原因是合作伙伴的里程碑收入延后及索乐匹尼布在中国的新药上市申请审评推迟。瑞银研报指出，和黄医药中期收入及肿瘤/免疫业务收入均低于预期，将H股目标价由37.7港元下调至36.9港元，但仍维持“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1588":"回港中概股","BK1191":"制药","00013":"和黄医药","BK1587":"次新股","HCM":"和黄医药"},"translate_title":"Revised down the full-year revenue guidance for the oncology business, Chi-Med's H shares closed down nearly 16% today, and U.S. stocks fell more than 5.5% before the market opened.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":0.9,"00013":1},"content_text":"和黄医药因下调肿瘤/免疫业务全年收入指引，导致H股今日收跌近16%，美股盘前跌超5.5%。公司上半年综合收入约2.8亿美元，同比跌9%；纯利逾4.5亿美元，同比增16.6倍。然而，肿瘤/免疫业务综合收入为1.4亿美元，同比跌15%。公司将全年收入指引从3.5亿-4.5亿美元下修至2.7亿-3.5亿美元，主要原因是合作伙伴的里程碑收入延后及索乐匹尼布在中国的新药上市申请审评推迟。瑞银研报指出，和黄医药中期收入及肿瘤/免疫业务收入均低于预期，将H股目标价由37.7港元下调至36.9港元，但仍维持“买入”评级。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557544747","isCrawlerRequest":true}